CYP19 Genetic Polymorphism & Aromatase Inhibitor(AI)

21:47 EST 26th November 2014 | BioPortfolio

Summary

The purpose of this study is to investigate the relationship between the side effects(especially arthralgia and arthritis) which appear in the patients who are prescribed aromatase inhibitor(AI) and the CYP19 genetic polymorphisms.

Study Design

Observational Model: Case-Only, Time Perspective: Prospective

Conditions

Breast Neoplasms

Intervention

Aromatase Inhibitor(Femara or Arimidex)

Location

Korea University Anam Hopital
Seoul
Korea, Republic of
136-705

Status

Recruiting

Source

Korea University Anam Hospital

Results (where available)

View Results

Links

Clinical Trials [1387 Associated Clinical Trials listed on BioPortfolio]

Study to Assess Effect of 8 Wks of Duloxetine Therapy on Breast Cancer Patients With Aromatase-Inhibitor Associated Pain

Many women with breast cancer who are treated with aromatase inhibitor medications develop aches and pains during treatment, and some develop numbness and tingling in their hands and feet....

Effect of Aromatase Inhibitors on Bones and Genes

The primary objective of this 2-year pilot project is to test the hypothesis that skeletal response to aromatase inhibitors is determined by polymorphisms of the CYP19 gene.

Treatment and Survival Continuation Study of Atamestane Plus Toremifene vs Letrozole in Advanced Breast Cancer

Protocol 777-CLP-32 is the treatment and survival continuation protocol of Biomed 777-CLP-29, and will continue to compare combined hormonal therapy using the experimental aromatase inhibi...

Aromatase Inhibitors for Treatment of Uterine Leiomyomas

Fibroids are benign tumors that might results in bleeding. Surgery is their definitive treatment. Some medical therapies have been tried for women who wish to preserve their uterus. Recent...

Study of XL147 or XL765 in Combination With Letrozole in Subjects With Breast Cancer

Phase 1 of this study will evaluate the maximum tolerated dose (MTD) of XL147 when given in combination with letrozole (Femara) and of XL765 when given in combination with letrozole. After...

PubMed Articles [7467 Associated PubMed Articles listed on BioPortfolio]

Long-term complete remission of metastatic breast cancer, induced by a steroidal aromatase inhibitor after failure of a non-steroidal aromatase inhibitor.

Patient: Female, 56 Final Diagnosis: Breast cancer Symptoms: Solid mass in the right breast Medication: Exemestane Clinical Procedure: - Specialty: Oncology.

Modification of Abdominal Fat Distribution After Aromatase Inhibitor Therapy in Breast Cancer Patients Visualized Using 3-D Computed Tomography Volumetry.

The purpose of this study was to describe modification of subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT) distributions in breast cancer patients after aromatase inhibitor (AI) the...

Bone Scan Alterations in Aromatase Inhibitor-Treated Patients.

We report bone scan changes in 3 patients receiving aromatase inhibitors as adjuvant treatment for postmenopausal hormone receptor-positive breast cancer. Compared with bone scans before treatment, re...

Tamoxifen through GPER upregulates aromatase expression: a novel mechanism sustaining tamoxifen-resistant breast cancer cell growth.

Tamoxifen resistance is a major clinical challenge in breast cancer treatment. Aromatase inhibitors are effective in women who progressed or recurred on tamoxifen, suggesting a role of local estrogen ...

Anastrozole may aid breast cancer prevention.

In the IBIS II Prevention Study, postmenopausal women at high risk of breast cancer given the aromatase inhibitor anastrozole were 53% less likely to develop the disease after 10 years than women who ...

Medical and Biotech [MESH] Definitions

A selective aromatase inhibitor effective in the treatment of estrogen-dependent disease including breast cancer.

An aromatase inhibitor that produces a state of "medical" adrenalectomy by blocking the production of adrenal steroids. It also blocks the conversion of androgens to estrogens. Aminoglutethimide has been used in the treatment of advanced breast and prostate cancer. It was formerly used for its weak anticonvulsant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p454)

Any neoplasms of the male breast. These occur infrequently in males in developed countries, the incidence being about 1% of that in females.

Neoplasms, usually carcinoma, located within the center of an organ or within small lobes, and in the case of the breast, intraductally. The emphasis of the name is on the location of the neoplastic tissue rather than on its histological type. Most cancers of this type are located in the breast.

Compounds that inhibit AROMATASE in order to reduce production of estrogenic steroid hormones.

More From BioPortfolio on "CYP19 Genetic Polymorphism & Aromatase Inhibitor(AI)"

Search BioPortfolio:
Loading
Advertisement

Relevant Topic

Breast Cancer
Latest News Clinical Trials Research Drugs Reports Corporate
Track and monitor developments in breast cancer research and commercial development.  Follow the tabs above to read the latest global news, research, clinical trials on breast cancer and follow companies active in the development of breast cancer tr...

Advertisement